ICD-10 D89.812 is officially defined as "Acute on chronic graft-versus-host disease." code D89.812 is referenced in 4 tracked payer policy changes from Blue Cross Blue Shield of North Dakota and Aetna. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code D89.812 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.
Blue Cross Blue Shield of North Dakota's August 2026 pharmacy update covers Medicaid Expansion medical drug prior authorization policies, with new policies and coding changes effective October 1, 2026. The most important billing change is the new HCPCS codes that replace older codes, such as Q5172 for Filkri and J9362 for Yondelis, plus added diagnosis codes for several drugs; the commercial pharmacy policies were reviewed with no changes listed.
Aetna's Clinical Policy Bulletin 0024 covers intravenous aldesleukin (Proleukin) for commercial medical plans and considers it medically necessary for unresectable or metastatic cutaneous melanoma, chronic graft-versus-host disease, neuroblastoma and metastatic renal cell carcinoma. Continuation of therapy for renal cell carcinoma or single-agent subsequent treatment of melanoma requires a response evaluation about 4 weeks after each course and again before the next course, further courses only when there is some tumor shrinkage after the last course, no contraindication to retreatment, and a rest period of at least 7 weeks from hospital discharge between courses. Aetna considers all other indications experimental, investigational, or unproven, and considers subcutaneous IL-2 experimental for renal cell carcinoma and all other indications except intralesional administration of IL-2 for melanoma.
Aetna considers aldesleukin (Proleukin) given intravenously medically necessary for metastatic renal cell carcinoma, cutaneous melanoma (as subsequent treatment of unresectable or metastatic disease given as high-dose single-agent therapy, or after an Amtagvi infusion for up to a maximum of 6 doses), chronic graft-versus-host disease that has not responded to first-line therapy, and neuroblastoma. Aetna considers all other indications experimental, investigational, or unproven, and considers subcutaneous IL-2 experimental for renal cell carcinoma and for all indications other than intralesional administration for melanoma. Continuation of therapy is medically necessary for renal cell carcinoma, single-agent subsequent cutaneous melanoma, chronic GVHD and neuroblastoma when the continuation criteria in the policy are met, and this policy applies to commercial medical plans.
For commercial plans, Aetna requires precertification of intravenous abatacept (Orencia IV) for all participating providers and members in applicable plan designs, and considers IV Orencia medically necessary only for members with a contraindication, intolerance or ineffective response to the listed equivalent targeted immune modulators. Abatacept is considered medically necessary for initial approval in rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, prophylaxis of acute graft versus host disease, chronic graft versus host disease, and immune checkpoint inhibitor-related myocarditis when the stated criteria are met, and continuation requires a positive clinical response. All other indications, and concurrent use with another biologic or targeted synthetic drug for the same indication, are considered experimental, investigational, or unproven.
Watch D89.812
Get one email when a payer policy names D89.812, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.
Get alerts for changes like this
Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.